The comparison of the efficacy of oral castor oil with vaginally misoprostol and vaginally misoprostol alone in the treatment of missed abortio
Phase 2
- Conditions
- treatment of missed abortion.Missed abortion Early fetal death with retention of dead fetus
- Registration Number
- IRCT201403244686N11
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 72
Inclusion Criteria
Inclusion criterion: missed abortion according sonography .
Exclusion criteria: sever anemia; sensitivity to prostaglandine; coaglopathy; acute liver disease; heart disease.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment of missed abortion. Timepoint: before intervention and four hour after intervention. Method of measurement: vaginal exam.
- Secondary Outcome Measures
Name Time Method Drug side effects. Timepoint: before intervention and four hour after intervention. Method of measurement: vaginal exam.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of castor oil in inducing uterine contractions for missed abortion management?
How does the combination of oral castor oil and vaginal misoprostol compare to misoprostol alone in terms of uterine evacuation success rates for early fetal demise?
Are there specific biomarkers that predict response to misoprostol-based regimens in patients with retained products of conception following missed abortion?
What are the potential adverse events associated with oral castor oil administration in combination with vaginal misoprostol for early fetal death management?
How do alternative prostaglandin analogs or combination therapies compare to vaginal misoprostol in treating early fetal retention?